Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio’s …
PRESS RELEASES
Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy
Pre-IND meeting with FDA completed with positive feedback on clinical and nonclinical development plans for PAS-nomacopan in treatment of geographic …
Akari Therapeutics Announces Interim CEO Employment Contract Demonstrating Alignment with Shareholders
• Interim CEO employment contract consists solely of equity compensation • Samir R. Patel, M.D., increases ownership to 14.2% with $1.25m …